美國健贊公司

用手机看条目

出自 MBA智库百科(https://wiki.mbalib.com/)

(重定向自Genzyme)
健赞公司(Genzyme Corporation)
健贊公司(Genzyme Corporation)

目錄

美國健贊公司簡介

  美國健贊公司(Genzyme Corporation, NASDAQ: GENZ)是全球較早成立的前十大生物製藥公司,也是前二十大納斯達克上市公司。其銷售產值排全球前十位,是生物製藥領域的五大企業之一。作為當今世界知名生物技術公司之一,健贊致力於研究和治療患有嚴重疾病的病人。於1981年成立於波士頓,現已成長為年收入超過30億美元,全球超過8000名員工的多樣化企業。一直致力於發展和應用生命科學中最先進的技術以服務於醫學的需要。它所生產產品和提供的醫學服務救助著超過80個國家的患者,其產品主要集中於罕見遺傳病、腎病、骨關節炎、免疫系統疾病和診斷測試。健贊公司至今仍在不斷創新,繼續研究開發基因遺傳、免疫系統疾病、心臟病和癌症等病癥。

  2011年,美國健贊公司為賽諾菲-安萬特收購

Genzyme Corporation

  One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 11,000 employees in locations spanning the globe and 2008 revenues of $4.6 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

  With many established products and services helping patients in nearly 100 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as cardiovascular disease, neurodegenerative diseases, and other areas of unmet medical need.

Overview of Genzyme Corporation

  Genzyme is one of the world’s leading biotechnology companies. Its more than 11,000 employees work in countries throughout the world and are united by a common goal: to make a major positive impact on the lives of people with debilitating diseases.

  Since its founding in 1981, Genzyme has grown from a small start-up to a diversified enterprise with 2008 revenues of $4.6 billion. Over the past two decades Genzyme has introduced a number of breakthrough treatments in several areas of medicine, which have provided hope to patients who previously had no viable treatment options. Genzyme products are helping patients in 100 countries.

  Today, Genzyme continues to be driven by its commitment to patients. The company is working to develop new medicines, improve its existing therapies, secure approvals for its products around the world, and ensure that patients have access to these treatments. Genzyme, which has its headquarters in Cambridge, Massachusetts, was chosen in 2007 to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

Genzyme focuses on the following broad areas of medicine:

  • Genetics Diseases
  • Cardiometabolic and Renal
  • Oncology
  • Orthopaedics/Biosurgical Specialties
  • Transplant
  • Genetics/Diagnostics

  Research and Development

  Genzyme's research and development efforts are focused on the areas of medicine where it markets commercial products. The company also conducts research in cardiovascular disease, neurodegenerative diseases, and other areas of unmet medical need. In 2008, Genzyme invested approximately $750 million in this work, or about 16 percent of its revenues.

  Genzyme continues to build its pipeline through both internal research and licensing and acquisitions, focusing on product candidates with the potential to change the standard of care for serious diseases. The company’s broad pipeline features seven major late-stage programs, including: alemtuzumab for multiple sclerosis; Clolar for adult acute myeloid leukemia; and mipomersen for familial hypercholesterolemia and other high risk, high cholesterol patients.

  Corporate Responsibility

  Corporate responsibility is a priority at Genzyme. The company’s commitment to patients extends beyond the development of new treatments and the services needed to deliver them. Genzyme has a strong presence in developing countries, where it provides free medicine to patients and helps to build sustainable health care systems. The company in 2006 launched an initiative to support the development of treatments for neglected diseases that affect hundred of millions of people in the developing world. Genzyme’s headquarters is one of the most environmentally responsible office buildings in the world, and the company is a leader in waste-reduction and recycling efforts.

  In addition, Genzyme supports science education and health initiatives in the communities in which it operates. For these and other efforts, Genzyme has been consistently included in the Dow Jones Sustainability World Index, which consists of companies that excel in economic, environmental and social performance. For the past three years, Genzyme was named one of the "Global 100 Most Sustainable Corporations in the World" by Innovest Strategic Value Advisors. BusinessWeek has ranked Genzyme as one of the top corporate givers, and the company has also been recognized by the U.S. Environmental Protection Agency, the American Association for the Advancement of Science, and many other organizations.

提示 本條目僅是MBA智庫百科美國健贊公司的介紹。若您需要與美國健贊公司聯繫,請訪問美國健贊公司官方網站。

本條目對我有幫助10
MBA智库APP

扫一扫,下载MBA智库APP

分享到:
  如果您認為本條目還有待完善,需要補充新內容或修改錯誤內容,請編輯條目

本条目由以下用户参与贡献

Cabbage,鲈鱼,方小莉,刘维燎,Llyn.

評論(共2條)

提示:評論內容為網友針對條目"美國健贊公司"展開的討論,與本站觀點立場無關。
42.236.240.* 在 2017年2月11日 12:30 發表

已退市 信息更新維護是個大問題

回複評論
58.212.98.* 在 2020年3月24日 18:17 發表

請問國內有銷售美國健贊產品角鯊烯GenzYme是真假丶

回複評論

發表評論請文明上網,理性發言並遵守有關規定。

打开APP

以上内容根据网友推荐自动排序生成

闽公网安备 35020302032707号